Preview

Атеротромбоз

Расширенный поиск

АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА ПРИ ПЕРВИЧНОЙ И ВТОРИЧНОЙ ПРОФИЛАКТИКЕ ИНСУЛЬТА

https://doi.org/10.21518/2307-1109-2017-1-54-66

Полный текст:

Аннотация

Профилактика инсульта остается одной из важнейших медицинских проблем. Ацетилсалициловая кислота (АСК) является единственным антитромботическим препаратом, применяемым с целью первичной и вторичной профилактики атеротромботического инсульта. Серьезным и труднопреодолимым ограничением к проведению активной антитромботической терапии при ишемическом инсульте является риск развития геморрагических осложнений, прежде всего внутричерепных кровоизлияний. При первичной профилактике инсульта у лиц без клинических проявлений атеросклероза особенно важно соотнести предполагаемую пользу и возможный риск от назначения АСК. Комбинация АСК с другими антитромбоцитарными препаратами (дипиридамол, клопидогрел) может принести дополнительную пользу у некоторых больных, перенесших инсульт или транзиторную ишемическую атаку.

 

 

Об авторе

П. С. Лагута
Институт кардиологии им. А.Л. Мясникова РКНПК МЗ РФ
Россия
к.м.н.


Список литературы

1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol, 2009, 8: 355-369.

2. Kathleen Strong K, Mathers C, Ruth Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol, 2007, 6: 182-187.

3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2014 update: a report from the American Heart Association. Circulation, 2014, 129: 28-292.

4. O’Donnell MJ, Xavier D, Liu L et al. INTERSTROKE Investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTER-STROKE study): a case-control study. Lancet, 2010, 376: 112-123.

5. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009, 373: 1849-60.

6. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Commitee of the Physicians’ Health Study Research Group. N. Engl. J. Med., 1989, 321: 129-35.

7. Peto R, Gray R, Collins R et al. Randomized trial of prophylactic daily aspirin in British male doctors. Br. Med. J., 1988, 296: 313-6.

8. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet, 1998, 351: 233-41.

9. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of Hypertension Optimal Treatment (HOT) random-ized trial. Lancet, 1988, 351: 1766-62.

10. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet, 2001, 357: 89-95.

11. Ridker P, Cook N, Min Lee L et. al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005, 352.

12. Seshasai SRK, Wijesuriya S, Sivakumaran R et.al. Effect of aspirin on vascular and non-vascular outcomes: meta-analysis of randomised controlled trials. Arch Intern Med, 2012, 172(3): 209-16.

13. Ogawa H, Nakayama M, Morimoto T et.al. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, 300(18): 2134-41.

14. Belch J, MacCuish A, Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br. Med. J., 2008, 337: a1840.

15. Fowkes FG, Price JF, Stewart MC et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA, 2010, 303(9): 841-8.

16. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2014, 45: 3754-3832.

17. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007, Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.

18. Pignone M, Alberts MJ, Colwell JA. Aspirin for Primary Prevention of Cardiovascular Events in people with diabetes. Circulation, 2010, 121: 2694-2701.

19. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA, 1992, 268: 1292-1300.

20. American Diabetes Association. Standarts of Medical Care in Diabetes — 2016. Diabetes Care, 2016, 39(s1): 56-57.

21. Criqui MH, Langer RD, Frontek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med., 1992, 326: 381-6.

22. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348: 1329-39.

23. Jardine MJ, Ninomiya T, Perkovic V et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a ran-domized controlled trial. J. Am. Coll. Cardiol., 2010, 56: 956-65.

24. Mancia G, Robert Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2013, 34: 2159-2219.

25. Dhamoon MS, Sciacca RR, Rundek T et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology, 2006, 66: 641-646.

26. McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324: 71-86.

27. Lansberg MG, O Donell MJ, Khatri P et. al. Antithrombotic and Thrombolytic therapy for ischemic stroke. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence — based Clinical Practice Guidelines. Chest, 2012, 141(2): 601-636.

28. The ESPS Group. The European Stroke Prevention Study: principal endpoints. Lancet, 1987, 2: 1351-1354.

29. Diener H, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci., 1996, 143: 1-13.

30. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet, 2006, 367: 1665-1673.

31. Sacco RL, Diener H-C, Yusuf S, Cotton D et al. for the PRoFESS Study Group. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med., 2008, 359: 1238-1251.

32. Diener H-C, Bogousslavsky J, Brass LM et al. MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): ran-domized, double-blind, placebo-controlled trial. Lancet, 2004, 364: 331-337.

33. Bhatt DL, Fox KA, Hacke W et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med., 2006, 354: 1706-1717.

34. Wang Y, Zhao X, Liu L et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N. Engl. J. Med., 2013, 369: 11-19.

35. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst. Rev., 2012, 9: CD001342.

36. Kernan WN, Ovbiagele B, Black HR. Guidelines for the Prevention of Stroke in patients with stroke and transient ischaemic attack. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-2236.

37. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. AHA Guidelines. Circulation, 2004, 109: 672-93.

38. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007, Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.


Для цитирования:


Лагута П.С. АЦЕТИЛСАЛИЦИЛОВАЯ КИСЛОТА ПРИ ПЕРВИЧНОЙ И ВТОРИЧНОЙ ПРОФИЛАКТИКЕ ИНСУЛЬТА. Атеротромбоз. 2017;(1):54-66. https://doi.org/10.21518/2307-1109-2017-1-54-66

For citation:


Laguta P.S. ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF STROKE. Atherothrombosis. 2017;(1):54-66. (In Russ.) https://doi.org/10.21518/2307-1109-2017-1-54-66

Просмотров: 305


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)